



## Berkshire West Area Prescribing Committee

<b>Drug Name</b>	Apomorphine (Apo-go®)
<b>Indication under review</b>	Treatment of Parkinson's disease
<b>Policy No:</b>	APC 045
<b>Date of Issue/Date of reissue:</b>	January 2014/March 2017
<b>Review Date:</b>	March 2020
<b>Traffic light status</b>	Amber
<b>Policy Statement:</b> Apomorphine (Apo-go®) is not recommended for routine use unless recommended by a specialist consultant with experience of treating Parkinson's Disease.	
<b>Key Points considered:</b> <ul style="list-style-type: none"> <li>• Available data indicate that apomorphine (Apo-go®) is superior to placebo but the studies had significant limitations.</li> <li>• In particular the data is short term therefore the long term safety, efficacy and cost effectiveness are not clear.</li> <li>• It is not clear if the patients included in the studies are representative of our local population.</li> <li>• As there is no comparative data with other treatment strategies it was decided that specialist input would be required to appropriately assess a place in the treatment of Parkinson's disease.</li> <li>• After careful consideration the committee agreed that there was insufficient evidence for routine use within primary care.</li> </ul>	
<b>References:</b> <ol style="list-style-type: none"> <li>1. NICE information available via : <a href="http://www.nice.org.uk/nicemedia/live/10984/30090/30090.pdf">http://www.nice.org.uk/nicemedia/live/10984/30090/30090.pdf</a></li> <li>2. Chen J J, Obering C. A review of intermittent subcutaneous apomorphine injections for the rescue management of motor fluctuations associated with advanced Parkinson's disease. <i>Clinical Therapeutics</i>. 2005;27(11):1710-1724</li> <li>3. Cochrane information available via : <a href="http://www.mrw.interscience.wiley.com/cochrane/cldare/articles/DARE-12006000532/frame.html">http://www.mrw.interscience.wiley.com/cochrane/cldare/articles/DARE-12006000532/frame.html</a></li> <li>4. Dewey et al. A Randomized, Double-blind, Placebo-Controlled Trial of Subcutaneously Injected Apomorphine for Parkinsonian Off-State Events. <i>Arch Neurol</i>. 2001;58:1385-1392</li> </ol>	
<b>Expired policy reviewed by APC:</b>	1 <sup>st</sup> March 2017
<b>Date ratified by the GP MOC:</b>	15 <sup>th</sup> March 2017

Berkshire West Area Prescribing Policies serve as a guide to clinicians. This does not overrule the clinical or budgetary responsibility of clinicians when considering treatment for individual patients.

Brown	Green	Amber	Red
These drugs have been reviewed and are not considered a cost effective use of scarce NHS resources	Medicines suitable for routine use. Primary care prescribers take full responsibility for prescribing	Medicines that should be initiated by a specialist and can be continued in primary care under a shared care agreement.	Medicines which should be prescribed by specialists only